Clarius Group buys $4,181,174 stake in Juno Therapeutics Inc (JUNO)

Juno Therapeutics Inc (JUNO) : Clarius Group scooped up 4,925 additional shares in Juno Therapeutics Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 10, 2016. The investment management firm now holds a total of 114,396 shares of Juno Therapeutics Inc which is valued at $4,181,174.Juno Therapeutics Inc makes up approximately 2.28% of Clarius Group’s portfolio.

Other Hedge Funds, Including , Norges Bank added JUNO to its portfolio by purchasing 468,600 company shares during the most recent quarter which is valued at $17,127,330. Juno Therapeutics Inc makes up approx 0.01% of Norges Bank’s portfolio.Tiaa Cref Investment Management boosted its stake in JUNO in the latest quarter, The investment management firm added 94,518 additional shares and now holds a total of 168,525 shares of Juno Therapeutics Inc which is valued at $6,264,074. Pacad Investment Ltd. added JUNO to its portfolio by purchasing 18,200 company shares during the most recent quarter which is valued at $676,494. Juno Therapeutics Inc makes up approx 0.08% of Pacad Investment Ltd.’s portfolio.State Of Wisconsin Investment Board reduced its stake in JUNO by selling 330 shares or 3.87% in the most recent quarter. The Hedge Fund company now holds 8,190 shares of JUNO which is valued at $304,422.

Juno Therapeutics Inc opened for trading at $36.85 and hit $38.35 on the upside on Monday, eventually ending the session at $38.16, with a gain of 4.40% or 1.61 points. The heightened volatility saw the trading volume jump to 6,61,286 shares. Company has a market cap of $4,027 M.

On the company’s financial health, Juno Therapeutics Inc reported $-0.78 EPS for the quarter, missing the analyst consensus estimate by $ -0.26 based on the information available during the earnings call on May 9, 2016. Analyst had a consensus of $-0.52. The company had revenue of $9.80 million for the quarter, compared to analysts expectations of $3.15 million. During the same quarter in the previous year, the company posted $-0.30 EPS.

Many Wall Street Analysts have commented on Juno Therapeutics Inc. Company shares were Reiterated by Maxim Group on Apr 11, 2016 to “Buy”, Firm has raised the Price Target to $ 80 from a previous price target of $78 .Citigroup Initiated Juno Therapeutics Inc on Feb 25, 2016 to “Buy”, Price Target of the shares are set at $45.Juno Therapeutics Inc was Upgraded by Guggenheim to ” Buy” on Feb 17, 2016.

Juno Therapeutics Inc. (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates JCAR015 JCAR017 and JCAR014 utilize CAR technology to target CD19 a protein expressed on the surface of various B cell leukemias and lymphomas. Juno’s other product candidates include JCAR018: CD22 JCAR023: L1CAM (CD171) JCAR020: MUC-16 / IL-12 ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial as a treatment for various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of AML myelodysplasic syndrome and chronic myeloid leukemia.

Leave a Reply

Juno Therapeutics Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Juno Therapeutics Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.